CSRC launches enzyme immuno-assay to detect lung cancer in all Norms

The European Society of Clinical Oncology (ESCO) has launched a new enzyme immuno-assay to spot patterns of gene mutations in very early in cancer patients.

CSRC (European League Against Lung Cancer) scientists at Barcelona Biocad Centre (CIB) and the Faculty of Medicine and Health Sciences of the Universitat Autnoma de Barcelona (UAB) in close collaboration with colleagues in Lyon and Genoa investigated a newly published protocol (PS-QSTABLE) for the analysis of the levels of half of the detected genes in a limited patient population (199 patients) who were monitored by a special blood test.

The new clinical initiative aims to give doctors a new tool for detecting early stage lung cancer cells that are in the early stages of the disease. The parameter is a new kind of fuel for the cancer immuno-assay meaning it allows us to intervene at very small dose and avoid unnecessary side-effects to the patients for example by avoiding immunotherapy or by scheduling a biopsy immediately–allowing us to see which patients are most likely to respond to checkpoint inhibitors says Dr Nadia Pucino head of CIBs Lung Cancer Prevention and Treatment Unit (CUPC). According to GP Blanca Almer The initiative will allow us to detect early stages of late stage secondary lung cancer who have never received treatment previously and has been clinically linked to the CPT-III the most active gene on the X-chromosome-rich Y-chromosome. This will greatly enhance knowledge that can be used to diagnose very specific types of patients and enable confidence in choosing the right research treatment. This can be especially important for patients who are diagnosed with late-stage family recurrence which accounts for one quarter of lung cancer deaths including CATCH which is resistant to all current treatment.